«TableStart:Samples»

Sample: «sample» Name: «patient» DOB: «dob» URN: «urn»

**SPECIMEN**

Block ID:block\_id, Tumour site: «site» Histology/Morphology: «morphology», Tumour cell content: «tumour\_pct» % tumour estimated in marked area

**INDICATION**

**Enter clinical details from request form including reason for testing**

**TARGETED CANCER PANEL** «isdraft»

**RESULT SUMMARY**

**This sample was not testable.**

**RESULT**

**FAILED SAMPLE**

**CLINICAL INTERPRETATION**

The specimen yielded insufficient quality or quantity of DNA for targeted cancer panel testing.

**CLINICAL RECOMMENDATIONS**

Testing of a repeat sample is required. Avoid FFPE tissue specimens with <20% tumour cell content, <5mm3 volume, mineral acid decalcified, or containing areas of necrosis or low cellularity.

**METHODOLOGY**

Tumour DNA was tested for mutations in 41 cancer related genes using a custom designed dual-stranded amplicon assay and Illumina TruSeq Amplicon Low Input chemistry. Target sequencing depth on Illumina MiSeq or NextSeq was 1000x. Alignment, variant calling and annotation were performed using a custom designed amplicon-optimised pipeline. Benign variants and variants of uncertain clinical effect are not reported.

**LIMITATIONS**

Only variants within target regions can be detected. Contact the laboratory for target region details. The assay has a limit of detection of approximately 5% minor allele frequency at 1000x coverage. This test is not suitable for detecting loss of heterozygosity, structural rearrangements or anueploidies. The test is unable to discriminate between somatic and inherited variants. Suspected germline variants should be confirmed on a separate sample.

**DISCLAIMERS**

While we make every effort to report accurate information, our recommendations may be based on evidence from third party data sources which draw on incomplete medical literature. Recommendations should be interpreted in the context of other clinical and laboratory findings, including tumour stage, purity, and histopathological classification.

This panel is classified as a Class 1–3 in-house IVD by NPAAC. Currently, not all targets in this gene panel can be fully validated to the current NPAAC requirements because control materials permitting determination of assay performance are not available for all genes on the panel. Results should be interpreted accordingly. For further information please contact the Laboratory.

*«TableEnd:Samples»*